Aaron Ondrey
Directeur Financier/CFO chez ROCKET PHARMACEUTICALS, INC.
Fortune : 997 371 $ au 31/05/2024
Postes actifs de Aaron Ondrey
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | Directeur Financier/CFO | 26/03/2024 | - |
Historique de carrière de Aaron Ondrey
Anciens postes connus de Aaron Ondrey
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| MIRATI THERAPEUTICS | Directeur Financier/CFO | 08/09/2023 | 23/01/2024 |
| Corporate Officer/Principal | 01/07/2022 | 08/09/2023 | |
| REGENERON PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/03/2010 | 01/11/2018 |
Formation de Aaron Ondrey
| Case Western Reserve University | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 5 |
Opérationnelle
| Director of Finance/CFO | 2 |
| Corporate Officer/Principal | 2 |
| Undergraduate Degree | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ROCKET PHARMACEUTICALS, INC. | Health Technology |
| REGENERON PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Mirati Therapeutics, Inc.
 Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
- Bourse
- Insiders
- Aaron Ondrey
- Expérience
